IRIS
FERRARA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.597
EU - Europa 2.556
NA - Nord America 2.289
SA - Sud America 314
Continente sconosciuto - Info sul continente non disponibili 151
AF - Africa 35
AN - Antartide 1
OC - Oceania 1
Totale 8.944
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.097
SG - Singapore 2.078
RU - Federazione Russa 1.253
IT - Italia 651
CN - Cina 582
HK - Hong Kong 373
RO - Romania 267
BR - Brasile 254
BD - Bangladesh 222
VN - Vietnam 173
FR - Francia 104
CA - Canada 88
GB - Regno Unito 74
DE - Germania 45
MX - Messico 44
NL - Olanda 33
IN - India 30
AR - Argentina 23
PL - Polonia 20
TR - Turchia 20
SE - Svezia 18
AT - Austria 17
ES - Italia 17
ZA - Sudafrica 17
ID - Indonesia 14
FI - Finlandia 13
IQ - Iraq 12
JP - Giappone 12
LT - Lituania 12
JM - Giamaica 11
UA - Ucraina 11
CR - Costa Rica 10
SA - Arabia Saudita 10
EC - Ecuador 9
TT - Trinidad e Tobago 9
AE - Emirati Arabi Uniti 8
CO - Colombia 8
PK - Pakistan 8
VE - Venezuela 8
MY - Malesia 7
NI - Nicaragua 7
HN - Honduras 6
PH - Filippine 6
GT - Guatemala 5
NP - Nepal 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
IE - Irlanda 4
JO - Giordania 4
KZ - Kazakistan 4
MA - Marocco 4
UY - Uruguay 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
BB - Barbados 3
ET - Etiopia 3
IL - Israele 3
SV - El Salvador 3
TH - Thailandia 3
BE - Belgio 2
BH - Bahrain 2
BO - Bolivia 2
CH - Svizzera 2
CW - ???statistics.table.value.countryCode.CW??? 2
KH - Cambogia 2
KR - Corea 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
PY - Paraguay 2
TW - Taiwan 2
AL - Albania 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BZ - Belize 1
CI - Costa d'Avorio 1
CL - Cile 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GD - Grenada 1
GR - Grecia 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
KE - Kenya 1
LV - Lettonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 8.794
Salva come PNG Salva come JPEG
Città #
Hong Kong 369
San Jose 329
Ashburn 315
Singapore 313
Moscow 268
Beijing 159
Dallas 142
Milan 142
Council Bluffs 131
New York 105
Hefei 96
Lauterbourg 80
Phoenix 74
Rome 67
Santa Clara 66
Ho Chi Minh City 61
Los Angeles 60
Hanoi 27
Mexico City 25
São Paulo 24
Denver 22
Naples 21
Miano 20
Montreal 19
Orem 19
Toronto 19
Chicago 18
Boston 17
Bologna 15
Buffalo 15
Florence 15
Houston 14
Pasadena 14
Warsaw 14
Munich 13
Shanghai 13
Brooklyn 12
Manchester 12
Vienna 12
Atlanta 11
Da Nang 11
Stockholm 11
Brescia 10
Johannesburg 10
North Bergen 10
Omaha 10
Rio de Janeiro 10
Turin 10
Ankara 9
Cesano Boscone 9
Haiphong 9
Poplar 9
Boardman 8
Catania 8
Chennai 8
Falkenstein 8
Frankfurt am Main 8
Helsinki 8
Miami 8
Tokyo 8
Verona 8
Amsterdam 7
Bari 7
Kingston 7
London 7
Managua 7
Nuremberg 7
Tampa 7
Tianjin 7
Venice 7
Assago 6
Brasília 6
Figino 6
Guangzhou 6
Hangzhou 6
Kyiv 6
Las Vegas 6
San José 6
Seattle 6
Trieste 6
Can Tho 5
Cleveland 5
Goiânia 5
Iesi 5
Istanbul 5
Jacksonville 5
Knoxville 5
Kuala Lumpur 5
Milwaukee 5
Palermo 5
Parma 5
Philadelphia 5
Porto Alegre 5
Querétaro 5
Riyadh 5
Rotherham 5
Washington 5
Adams Center 4
Aurora 4
Baghdad 4
Totale 3.578
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 402
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 250
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 241
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) 206
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system 201
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer 200
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 198
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake 197
OncoAlert Round Table Discussions: The Global COVID-19 Experience 193
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors 183
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 183
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy 174
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 139
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC 130
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 123
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial 120
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer 114
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 111
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 110
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? 109
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) 105
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation 99
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer 98
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 97
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program 97
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression 94
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC 93
Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study 91
Hyperprogressive disease: recognizing a novel pattern to improve patient management 89
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 89
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers 88
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study 87
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy 86
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer 85
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy 84
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 80
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 79
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer 79
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria 77
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 77
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer 76
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter 75
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort 75
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy 75
A Case of William's Syndrome in a Ugandan Child: A Feasible Diagnosis Even in a Low-Resource Setting 74
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors 74
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out 73
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 73
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation 73
Atypical patterns of response and progression in the era of immunotherapy combinations 71
Immunotherapy 70
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? 70
SMO mutations confer poor prognosis in malignant pleural mesothelioma 69
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors 68
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy 68
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors 68
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC 67
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 67
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer 67
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases 63
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments 61
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors 61
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy 61
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 61
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective 61
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer 59
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy 59
Do immune checkpoint inhibitors need new studies methodology? 59
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events 58
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 57
Progress in the Management of Advanced Thoracic Malignancies in 2017 57
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients 57
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma 57
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer 56
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? 55
Wide and Cystic Brain Metastases Reveal RET-Rearranged Non-Small-Cell Lung Cancers 54
The development of PARP as a successful target for cancer therapy 53
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 53
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis 53
Unexpected Huge Prevalence of Intracardiac Extension of Wilms Tumor—A Single Center Experience from a Ugandan Hospital 52
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 52
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? 50
The Anti–Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers 50
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean? 48
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients 48
Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply 47
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 47
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 45
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 44
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations 44
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 44
How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer 44
Robotic Surgery Is a Safe Treatment in Very Elderly Patients with Resectable Lung Cancer 44
Is hyperprogressive disease a specific phenomenom of immunotherapy? 43
Multidisciplinary management of N2 stage III non-small cell lung cancer: opportunities and challenges for radiation oncology 43
A viable human lung cancer tissue collection (LCTC) to accelerate translational research 41
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy-Reply 39
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis 30
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 27
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities 25
Totale 8.773
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.824
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.824
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202314 3 2 1 0 0 1 1 2 0 0 2 2
2023/202440 2 4 2 2 2 5 6 3 3 3 1 7
2024/20252.532 16 6 1 6 9 7 404 66 214 300 761 742
2025/20264.780 383 308 146 440 413 170 417 321 1.282 300 251 349
2026/20271.576 268 442 299 567 0 0 0 0 0 0 0 0
Totale 8.944